Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Alfadhli

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Gastroenterology Clinics of North America|June 5, 2004
Methotrexate in inflammatory bowel diseaseBrian G Feagan, Ahmad Alfadhli
Vaccines|July 27, 2022
COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional StudyMohammad Shehab, Fatema Alrashed, Ahmad Alfadhli
Infection Prevention in Practice|July 28, 2021
Effectiveness of inspectors' team in increasing compliance with personal protective equipment use and reducing COVID19 infection spread among healthcare workersMohammad Shehab, Sameera Shuaibi, Iman Qadhi, et al.
Frontiers in Pharmacology|October 25, 2023
Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)Fatema Alrashed, Israa Abdullah, Ahmad Alfadhli, et al.
Medicine|July 5, 2024
Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide retrospective study (TARGET STUDY)Mohammad Shehab, Israa Abdullah, Ahmad Alfadhli, et al.
Journal of Global Infectious Diseases|October 14, 2022
A Randomized Clinical Trial Comparing Triple Therapy versus Non-bismuth based Quadruple Therapy for the Eradication of <i>Helicobacter Pylori</i> in KuwaitAhmad Alfadhli, Mohamed Alboraie, Mostafa Afifi, et al.
Diagnostics (Basel, Switzerland)|November 9, 2024
Predictive Factors of Significant Findings on Capsule Endoscopy in Patients with Suspected Small Bowel BleedingAli A Alali, Reem Alrashidi, Farah Allahow, et al.
Vaccines|January 22, 2022
COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional StudyMohammad Shehab, Yasmin Zurba, Ali Al Abdulsalam, et al.
Frontiers in Pharmacology|October 31, 2024
Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study)Mohammad Shehab, Ahmad Alfadhli, Israa Abdullah, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 13, 2025
Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross-Sectional StudyMohammad Shehab, Abdulwahab Alsayegh, Munirah Alabdulhadi, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Gastroenterology Clinics of North America|June 5, 2004
Methotrexate in inflammatory bowel diseaseBrian G Feagan, Ahmad Alfadhli
Vaccines|July 27, 2022
COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional StudyMohammad Shehab, Fatema Alrashed, Ahmad Alfadhli
Infection Prevention in Practice|July 28, 2021
Effectiveness of inspectors' team in increasing compliance with personal protective equipment use and reducing COVID19 infection spread among healthcare workersMohammad Shehab, Sameera Shuaibi, Iman Qadhi, et al.
Frontiers in Pharmacology|October 25, 2023
Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)Fatema Alrashed, Israa Abdullah, Ahmad Alfadhli, et al.
Medicine|July 5, 2024
Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide retrospective study (TARGET STUDY)Mohammad Shehab, Israa Abdullah, Ahmad Alfadhli, et al.
Journal of Global Infectious Diseases|October 14, 2022
A Randomized Clinical Trial Comparing Triple Therapy versus Non-bismuth based Quadruple Therapy for the Eradication of <i>Helicobacter Pylori</i> in KuwaitAhmad Alfadhli, Mohamed Alboraie, Mostafa Afifi, et al.
Diagnostics (Basel, Switzerland)|November 9, 2024
Predictive Factors of Significant Findings on Capsule Endoscopy in Patients with Suspected Small Bowel BleedingAli A Alali, Reem Alrashidi, Farah Allahow, et al.
Vaccines|January 22, 2022
COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional StudyMohammad Shehab, Yasmin Zurba, Ali Al Abdulsalam, et al.
Frontiers in Pharmacology|October 31, 2024
Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study)Mohammad Shehab, Ahmad Alfadhli, Israa Abdullah, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 13, 2025
Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross-Sectional StudyMohammad Shehab, Abdulwahab Alsayegh, Munirah Alabdulhadi, et al.
Pageof 3